A randomized, single-blind, placebo-controlled study of the effects of repeat doses of NT-814 on oestradiol and other sex hormone concentrations in healthy pre-menopausal female volunteers
Latest Information Update: 02 Mar 2021
At a glance
- Drugs Elinzanetant (Primary)
- Indications Sex hormone disorders; Sleep disorders; Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors KaNDy Therapeutics; NeRRe Therapeutics
- 24 Feb 2021 Results published in the Journal of Clinical Endocrinology and Metabolism
- 22 Sep 2020 New trial record